| Q58735997 | Q58735997 |
| Q39077342 | A Prediction Model to Help with the Assessment of Adenopathy in Lung Cancer: HAL. |
| Q30250349 | Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer |
| Q41701274 | Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society o |
| Q38176433 | Controversies in the management of stage III non-small-cell lung cancer |
| Q35852897 | Determinants of practice patterns and quality gaps in lung cancer staging and diagnosis |
| Q44243147 | Effects of multiple factors on the prognosis of pIIIa/N2 patients with non-small cell lung cancer |
| Q35188381 | Endoscopic ultrasound-guided biopsies for mediastinal lesions and lymph node diagnosis and staging |
| Q41989025 | Feasibility and long-term efficacy of video-assisted thoracic surgery for unexpected pathologic N2 disease in non-small cell lung cancer |
| Q35036508 | Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT. |
| Q37478345 | Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer |
| Q35573028 | Invasive mediastinal staging of non-small-cell lung cancer: a clinical practice guideline |
| Q36788474 | Is 18F FDG PET-CT cost effective in lung cancer? |
| Q53480253 | It's all about US: (E)US, (EB)US, and their US(age). |
| Q35923256 | Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis |
| Q37217756 | Lung cancer surgery: an up to date |
| Q36835924 | Lung cancer: new surgical approaches |
| Q36107597 | Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound |
| Q38007233 | Mediastinal staging of lung cancer: novel concepts |
| Q34094782 | N2 disease in T1 non-small cell lung cancer |
| Q35941636 | Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis |
| Q36299306 | Nomogram to Predict Occult N2 Lymph Nodes Metastases in Patients With Squamous Nonsmall Cell Lung Cancer |
| Q24187743 | PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer |
| Q37301288 | Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). |
| Q37456466 | Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer |
| Q35968871 | Postoperative radiotherapy for elderly patients with stage III lung cancer |
| Q92566329 | Preoperative Risk Factors for Pathologic N2 Metastasis in Positron Emission Tomography-Computed Tomography-Diagnosed N0-1 Non-Small Cell Lung Cancer |
| Q35852907 | Quality gaps and comparative effectiveness in lung cancer staging and diagnosis |
| Q46798055 | Role of mediastinoscopy and repeat mediastinoscopy today |
| Q34031208 | Surgical strategies in the therapy of non-small cell lung cancer |
| Q36653508 | Systematic Endobronchial Ultrasound-guided Mediastinal Staging Versus Positron Emission Tomography for Comprehensive Mediastinal Staging in NSCLC Before Radical Radiotherapy of Non-small Cell Lung Cancer: A Pilot Study |
| Q47141436 | Unless I see, I will not believe. |